Phase II trials of interferons-alpha and -beta in advanced sarcomas.

Abstract

Interferons (IFNs)-alpha and -beta were administered to patients with metastatic sarcomas in two different Eastern Cooperative Oncology Group studies. In one study, patients received IFN-alpha 2b, 20 million units/m2 i.v. 5 days/week x 4, then 10 million units s.c.t.i.w. In the second study, patients received IFN-beta ser 180 million units t.i.w. Of 87 patients evaluable for response, there were three responses in 64 patients (5%) treated with IFN-alpha-2b and no responses in 23 patients treated with IFN-beta ser. Severe or life-threatening fatigue with decline in performance status complicated treatment of 37% of patients receiving IFN-alpha 2b and 17% of patients receiving IFN-beta ser. Further investigation of IFNs in sarcomas should depend on evidence from preclinical studies demonstrating synergistic effects of IFNs combined with a cytoreductive modality which has proven activity in these malignancies.

• Authors: E C Borden, K Kim, L Ryan, R H Blum, M Shiraki, D C Tormey, R L Comis, R G Hahn, D R Parkinson
• Journal: Journal of interferon research (J Interferon Res) Vol. 12 Issue 6 Pg. 455-8 (Dec 1992) ISSN: 0197-8357 [Print] United States
• PMID: 1289413 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Interferon beta-1b
• Interferon-beta
• Interferon beta-1a

Topics

• Adult
• Aged
• Drug Administration Schedule
• Female
• Humans
• Infusions, Intravenous
• Injections, Subcutaneous
• Interferon alpha-2
• Interferon beta-1a
• Interferon beta-1b
• Interferon-alpha (therapeutic use)
• Interferon-beta (therapeutic use)
• Male
• Middle Aged
• Recombinant Proteins
• Sarcoma (secondary, therapy)
• Soft Tissue Neoplasms (therapy)
• Treatment Outcome